Track record · closed signal

Berkshire Hathaway Inc. Class B (BRK-B) — closed signal from July 9, 2025

Partial Published before the outcome was known, scored automatically when the window closed on October 7, 2025.

Predicted vs. what happened

BRK-B price · publication thesis → realized outcomesplit-adjusted
$477.47 Published $525.22 Target $502.30 Window close $507.66 Peak
$455.00 – $465.00Entry zone — fair-value band
$477.47Published — price the day we called it
$525.22Target — the price the thesis aimed for
$507.66Peak — highest point inside the window, not a realized return
$502.30Window close — end-of-window price, context only

What happened

Partial

Reached 63% of the predicted growth at its peak, without hitting the target.

Peak price
$507.66
peak on September 5, 2025 — not a realized return
Peak gain
+6.3%
peak, from the publication price
Window close
$502.30
end-of-window price, context only
Days to target
Window
July 9, 2025 – October 7, 2025

The thesis — published July 9, 2025

Predicted growth
+10%
over the measurement window
Target price
$525.22
the price the thesis aimed for
Entry zone
$455.00 – $465.00
the fair-value band we waited for
Price at publication
$477.47
published July 9, 2025
Confidence
67%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

The share price slid 7%, and a rare oversold signal that has usually been followed by a 9% bounce within roughly two months just flashed. Berkshire also sits on a huge $189 billion cash reserve it can use to buy back its own stock, which often pushes prices up. UBS, a large investment bank, still rates the shares a Buy even after trimming its target slightly. All this points to a possible move back toward $520 once the recent wave of selling fades.

Primary drivers

  • Berkshire's $189 billion cash lets it repurchase plenty of its own stock.
  • A rare indicator shows the stock is very beat-up and often rebounds.
  • UBS still says Buy even after nudging its target lower, creating a dip chance.
  • Rising insurance prices should improve Berkshire's profit mix.

How it played out

BRK-B: thesis partly played out, target missed

Lyra published BRK-B on 2025-07-09 at $477.47. The thesis expected 10% growth toward $525.22. It pointed to a 7% slide, a rare oversold signal that had often been followed by a 9% bounce within roughly two months, Berkshire's $189 billion cash reserve for possible buybacks, a UBS Buy rating, and rising insurance prices.

Inside the window, the stock rose, but not enough. It peaked at $507.66 on 2025-09-05, a 6.3% gain, and stayed below the target. It ended at $502.30 on 2025-10-07. The thesis partly played out. It never got there.

What happened during the window

On 2025-08-02, Berkshire reported second-quarter 2025 operating earnings of $11,160 million and net earnings attributable to shareholders of $12,370 million. On 2025-10-02, Berkshire and Occidental announced a definitive agreement for Berkshire to acquire OxyChem in an all-cash transaction for $9.7 billion.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.